The duration of lithium use and biological ageing: telomere length,

frailty, metabolomic age and all-cause mortality

- †Julian Mutz^{1*}, †Win Lee Edwin Wong^{2, 3, 4}, Timothy R. Powell¹, Allan H. Young^{4, 5}, Gavin 4
- S. Dawe^{2, 3, 6} & Cathryn M. Lewis^{1, 7} 5

1

2

3

6

21

23

- 7 1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
- 8 Psychology & Neuroscience, King's College London, London, United Kingdom.
- 9 2. Department of Pharmacology, Yong Loo Lin School of Medicine, National University 10 of Singapore, Singapore.
- 11 3. Healthy Longevity Translational Research Programme, Yong Loo Lin School of 12 Medicine, National University of Singapore, Singapore.
- 13 4. Department of Psychological Medicine, Institute of Psychiatry, Psychology & 14 Neuroscience, King's College London, London, United Kingdom.
- 15 5. South London & Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, London, United Kingdom. 16
- 17 6. Neurobiology Programme, Life Sciences Institute, National University of Singapore, 18 Singapore.
- 7. Department of Medical and Molecular Genetics, Faculty of Life Sciences and 19 Medicine, King's College London, London, United Kingdom. 20
- 22 †These authors contributed equally to this work and are designated as co-first authors.
- 24 *Corresponding author:
- 25 Dr Julian Mutz; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
- 26 Psychology & Neuroscience, King's College London, Memory Lane, London, SE5 8AF,
- 27 United Kingdom. Email: julian.mutz@gmail.com.

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

ABSTRACT Background: Lithium is an established first-line treatment for bipolar disorder. Beyond its therapeutic effect as a mood stabiliser, lithium exhibits potential anti-ageing effects. This study aimed to examine the relationship between the duration of lithium use, biological ageing and mortality. Methods: The UK Biobank is an observational study of middle-aged and older adults. We tested associations between the duration of lithium use (number of prescriptions, total duration of use, and duration of the first prescription period) and telomere length, frailty, metabolomic age, pulse rate and all-cause mortality. **Results**: 591 individuals (mean age = 57.49 years; 55% females) had been prescribed lithium. There was no evidence that the number of prescriptions ($\beta = -0.022, 95\%$ CI -0.081 to 0.037, p = 0.47), the total duration of use ($\beta = -0.005, 95\%$ CI -0.023 to 0.013, p = 0.57) or the duration of the first prescription period ($\beta = -0.018$, 95% CI -0.051 to 0.015, p = 0.29) correlated with telomere length. There was also no evidence that the duration of lithium use correlated with frailty or metabolomic age. However, a higher prescription count or a longer duration of use was associated with a lower pulse rate. The duration of lithium use did not predict mortality. Conclusions: We observed no evidence of associations between the duration of lithium use and biological ageing markers, including telomere length. Our findings suggest that the

potential anti-ageing effects of lithium do not differ by duration of use.

INTRODUCTION

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Lithium is considered the gold standard treatment for patients with bipolar disorder who experience recurrent episodes of (hypo)mania and depression. Lithium is also used to augment antidepressant medication, for example in patients with difficult-to-treat major depressive disorder.² While the evidence supports lithium's therapeutic effects,³ its mechanisms of action are incompletely understood. Studies indicate that lithium influences neurotransmitter signalling and acts on second messenger systems including the adenyl cyclase and protein kinase A pathways.4

Beyond its therapeutic effects as a mood stabiliser, multiple lines of evidence suggest that lithium may impact biological ageing and longevity.⁵ For example, mitochondrial dysfunction is a hallmark of ageing, 6 and lithium treatment has been shown to enhance mitochondrial metabolism by increasing the activity of electron transport complexes.^{7,8} Preclinical and clinical studies suggest that lithium can reduce oxidative stress, which is linked to several agerelated diseases.^{9,10} Notably, studies have demonstrated that lithium extends the lifespan of model organisms, including Caenorhabditis elegans ("C. elegans") and Drosophila. 11,12

A specific focus of research on lithium's potential anti-ageing properties has been to examine its link with telomere length. Telomeres, which are repetitive nucleoprotein complexes at the ends of chromosomes, progressively shorten with cell division and play an important role in maintaining genomic stability. Telomere attrition is a hallmark of ageing and is linked to cellular senescence.⁶ Telomere dysfunction plays a role in many human diseases.¹³ For example, meta-analyses suggest that individuals with bipolar disorder have shorter telomeres than healthy controls. 14-16 However, several studies have also found no evidence of a difference in telomere length or observed longer telomeres in patients with bipolar disorder. These inconsistencies may in part result from differences in lithium treatment. Some clinical studies suggest that lithium protects against telomere attrition. For example, studies have shown that bipolar disorder patients treated with lithium had longer telomeres than healthy controls¹⁷ and that lithium-treated patients had longer telomeres than patients who were not treated with lithium. 17,18. While these group differences in telomere length could be due to other factors, several studies found that a longer duration of lithium treatment was correlated with longer telomeres.¹⁹

80

81

82

83

84

85

86

Building on previous studies in the UK Biobank that have identified predictors and correlates of telomere length, ²⁰⁻²² we examined the potential impact of the duration of lithium treatment on telomere length and other markers of biological ageing. We defined three measures of lithium treatment duration using primary care prescription records and assessed multiple markers of biological ageing and longevity, including telomere length, frailty, metabolomic age and all-cause mortality. The overall aim was to elucidate the broader implications of lithium treatment on biological ageing.

METHODS

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Study population

The UK Biobank is a prospective community-based study that recruited more than 500,000 middle-aged and older adults, aged 40 to 69 years.²³ Individuals who were registered with the UK National Health Service (NHS) and lived within a 25-mile (~40 km) radius of one of 22 assessment centres were invited to participate. At the baseline assessment, which took place between 2006 and 2010, participants reported their sociodemographic characteristics, health behaviours and medical history. They also underwent physical examinations and had blood and urine samples taken. Data linkage to primary care health records is available for about 230,000 participants.

Duration of lithium use

The duration of lithium use was derived from medication prescriptions recorded by general practitioner practices as part of routine patient care. These data included prescriptions recorded between July 1945 and September 2017 and were available for 222,073 participants. Lithium prescriptions were identified using a combination of the British National Formulary (BNF), Read v2 and Dictionary of Medicines and Devices (dm+d) codes, and by searching for relevant string permutations across the prescription medication names. The duration of lithium use was defined in three ways, similar to our previous study on antidepressants.²⁴ First, we calculated the total number of lithium prescriptions across all primary care prescription records. Second, we calculated the total number of weeks across all prescription windows, which we defined as periods of less than 90 days between consecutive prescriptions. Third, we calculated the number of weeks of the first prescription window. Prescriptions after the baseline assessment date were excluded from these calculations.

Telomere length

Leukocyte telomere length was measured using a quantitative polymerase chain reaction (PCR) assay that expresses telomere length as the ratio of the telomere repeat copy number (T) relative to a single-copy gene (S) that encodes haemoglobin subunit beta. ²⁵ The T/S ratio is proportional to an individual's average telomere length.²⁶ Measurements were adjusted for operational and technical parameters (PCR machine, staff member, enzyme batch, primer batch, temperature, humidity, primer batch × PCR machine, primer batch × staff member, A260/A280 ratio of the DNA sample and A260/A280 ratio squared), loge transformed and Z-standardised.

Frailty index

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

A frailty index was derived from health deficits that met the following criteria: indicators of poor health; more prevalent in older individuals; neither rare nor universal; covering multiple areas of functioning; available for > 80% of participants.²⁷ The index included 49 variables ascertained via touch-screen questionnaires and nurse-led interviews. cardiometabolic, cranial, immunological, musculoskeletal, respiratory, and sensory traits, wellbeing, infirmity, cancer, and pain. Categorical variables were dichotomised (no deficit = 0; deficit = 1), and ordinal variables were mapped onto a score between zero and one. The sum of deficits was divided by the total number of possible deficits, resulting in frailty index scores between zero and one, with higher scores indicating greater levels of frailty.²⁸ Participants with missing data for > 10/49 variables were excluded.²⁷

Metabolomic ageing clock

Nuclear magnetic resonance (NMR) spectroscopy-derived metabolomic biomarkers were quantified in non-fasting plasma samples using the Nightingale Health platform, which ascertains 168 circulating metabolites using a high-throughput standardised protocol.²⁹ In 101,359 participants, we developed a metabolomic ageing clock using a Cubist rule-based regression model. This algorithm is an ensemble technique that derives rules from decision trees and fits linear regression models in the subsets of data defined by these rules. The model incorporates boosting techniques and may adjust predictions based on k-nearest neighbors.^{30,31} Model performance was assessed using nested cross-validation with 10 outer loops and 5 inner folds for hyperparameter tuning. The cross-validation mean absolute error (MAE) was 5.42 years. Metabolomic age (MileAge) delta represents the difference between predicted and chronological age, with positive and negative values indicating accelerated and decelerated biological ageing, respectively.

Pulse rate

Resting pulse rate in beats per minute was recorded using an Omron 705 IT digital blood pressure monitor device or, exceptionally, a manual sphygmomanometer. We calculated the average of the two available readings to reduce potential measurement error.

All-cause mortality

The date of death was obtained through linkage with national death registries: NHS Digital (England and Wales) and the NHS Central Register (Scotland). The censoring date was 30

November 2022. The most recent death was recorded on 19 December 2022, although the data were incomplete for December 2022.

Covariates

155

156

157

158

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

- 159 Covariates for the cross-sectional and prospective analyses included chronological age, sex.
- 160 body mass index (kg/m²), morbidity count (none/one, two, three, four or five+), gross annual
- 161 household income (<£18,000, £18,000-£30,999, £31,000-£51,999 or £52,000-£100,000 /
- >£100,000), highest educational/professional qualification (none, O levels/GCSEs/CSEs, A 162
- 163 levels/NVQ/HND/HNC or degree) and cohabitation status (single or with spouse/partner).

Statistical analyses

The data processing and analyses were performed in R (version 4.2). Sample characteristics were summarised using means and standard deviations or counts and percentages. Associations between the duration of lithium use (number of prescriptions, total duration of use, and duration of the first prescription period) and telomere length were estimated using ordinary least squares regression. We further tested associations between the duration of lithium use and two other indicators of biological age, the frailty index and the metabolomic ageing clock, and pulse rate. Hazard ratios (HRs) and 95% confidence intervals were estimated using Cox proportional hazards models to examine associations between the duration of lithium use and all-cause mortality. We examined both quintiles of the distribution, with the lowest quintile as the reference group, and spline functions of the distribution with the median as reference value. Age in years was used as the underlying time axis, with age 40 as the start of follow-up. The cross-sectional and prospective analyses were adjusted for chronological age and sex (Model 1) and chronological age, sex, body mass index, morbidity count, household income, highest qualification, and cohabitation status (Model 2).

Sensitivity analyses

We conducted the following sensitivity analyses of the duration of lithium use and biological ageing markers: we restricted the sample to individuals with a total duration of lithium use of (a) at least 1 year (52 weeks) or (b) at least 4.5 years (234 weeks); we additionally adjusted for current antidepressant medication use (yes/no) at the time of the baseline assessment.

RESULTS

186

187

188

189

190

191

192

193

194

195

Sample characteristics

Of the 502,476 participants in the UK Biobank, 222,073 individuals (about 44.2% of the sample) had prescription data available through their linked primary care records. Of the 773 participants with a lithium prescription in their primary care record, n = 182 were excluded because their first prescription followed the baseline assessment. The duration of lithium use was estimated for 591 participants (Figure S1). Sample characteristics are shown in Table 1. Based on our previously reported criteria, 32,33 71.74% of participants had a lifetime history of mood disorders (n = 248 had bipolar disorder and n = 176 had depression).

Table 1. Sample characteristics

	Lithium duration	Primary care	No primary care ¹ (<i>N</i> =280,403)		
	(N=591)	(N=221,482)			
Age; mean (SD)	57.49 (7.51)	56.58 (8.05)	56.48 (8.13)		
Sex					
Female	327 (55.3%)	121618 (54.9%)	151420 (54.0%)		
Male	264 (44.7%)	99864 (45.1%)	128982 (46.0%)		
Ethnicity					
White	572 (96.8%)	210119 (94.9%)	261977 (93.4%)		
Non-White	14 (2.4%)	10322 (4.7%)	16695 (6.0%)		
Missing ²	5 (0.8%)	1041 (0.5%)	1731 (0.6%)		
Highest qualification					
None	119 (20.1%)	39882 (18.0%)	45265 (16.1%)		
O levels/GCSEs/CSEs	125 (21.2%)	58292 (26.3%)	73662 (26.3%)		
A levels/NVQ/HND/HNC ³	118 (20.0%)	50521 (22.8%)	63207 (22.5%)		
Degree	222 (37.6%)	69916 (31.6%)	91014 (32.5%)		
Missing ²	7 (1.2%)	2871 (1.3%)	7255 (2.6%)		
Household income ⁴					
Very low	198 (33.5%)	45278 (20.4%)	51717 (18.4%)		
Low	132 (22.3%)	49247 (22.2%)	58794 (21.0%)		
Medium	95 (16.1%)	49037 (22.1%)	61637 (22.0%)		
High / Very high	72 (12.2%)	45305 (20.5%)	63809 (22.8%)		
Missing ²	94 (15.9%)	32615 (14.7%)	44446 (15.9%)		
Cohabitation					
With partner	359 (60.7%)	160735 (72.6%)	201961 (72.0%)		
Single	55 (9.3%)	17885 (8.1%)	24172 (8.6%)		
Missing ²	177 (29.9%)	42862 (19.4%)	54270 (19.4%)		
Smoking status					
Never	293 (49.6%)	121023 (54.6%)	152188 (54.3%)		
Former	186 (31.5%)	76153 (34.4%)	96711 (34.5%)		
Current	106 (17.9%)	23143 (10.4%)	29724 (10.6%)		
Missing ²	6 (1.0%)	1163 (0.5%)	1780 (0.6%)		
Morbidity count		, ,	` '		
None / One	119 (20.1%)	108494 (49.0%)	140930 (50.3%)		
Two	150 (25.4%)	44962 (20.3%)	55724 (19.9%)		
	` /	` ,	` '		

Three	116 (19.6%)	29465 (13.3%)	36037 (12.9%)
Four	77 (13.0%)	17297 (7.8%)	20903 (7.5%)
Five+	126 (21.3%)	20903 (9.4%)	26310 (9.4%)
Missing ²	3 (0.5%)	361 (0.2%)	499 (0.2%)
Baseline lithium Rx ⁵	, ,	, ,	, ,
No	296 (50.1%)	204499 (92.3%)	252446 (90.0%)
Yes	261 (44.2%)	83 (0.0%)	417 (0.1%)
Missing ²	34 (5.8%)	16900 (7.6%)	27540 (9.8%)
Baseline cholesterol Rx ⁵	, ,		, ,
No	425 (71.9%)	171354 (77.4%)	217473 (77.6%)
Yes	161 (27.2%)	48000 (21.7%)	57335 (20.4%)
Missing ²	5 (0.8%)	2128 (1.0%)	5595 (2.0%)
Fasting time			
Less than 8 hours	563 (95.3%)	211768 (95.6%)	267565 (95.4%)
At least 8 hours	24 (4.1%)	9179 (4.1%)	12143 (4.3%)
Missing ²	4 (0.7%)	535 (0.2%)	695 (0.2%)
Body mass index; mean (SD) ⁶	28.70 (5.34)	27.54 (4.83)	27.34 (4.78)

Note: Numbers shown are counts and percentages unless indicated otherwise. SD = standard deviation; GCSEs = general certificate of secondary education; CSE = certificate of secondary education; NVO = national vocational qualification; HND = higher national diploma; HNC = higher national certificate; Rx = prescription. ¹ Information on age and sex was missing for one participant in the sample without linked primary care data. ² Missing data also includes "do not know", "prefer not to answer" or "not applicable". 3 Also includes 'other professional qualifications'. ⁴ Annual household income groups: very low (<£18,000), low (£18,000– £30,999), middle (£31,000–£51,999), high (£52,000–£100,000) and very high (>£100,000). 5 Prescriptions refer to *current* medication use at the time of the baseline assessment. ⁶ Missing data for body mass index: n = 10, n = 1344 and n = 1751.

Duration of lithium use and telomere length

196

197

198

199

200

201

202

203

204

205

206

In the model adjusted for chronological age and sex, there was no evidence that the number of lithium prescriptions (N = 569, $\beta = -0.022$, 95% CI -0.081 to 0.037, p = 0.47), the total duration of use $(N = 569, \beta = -0.005, 95\% \text{ CI } -0.023 \text{ to } 0.013, p = 0.57)$ or the duration of the first prescription period (N = 569, $\beta = -0.018$, 95% CI -0.051 to 0.015, p = 0.29) were associated with telomere length. Additional adjustment for body mass index, morbidity count, household income, highest qualification and cohabitation status had no discernible impact on these results (Table 1). Individuals with a higher prescription count or longer duration of lithium use were more likely to use lithium at the time of the baseline assessment (Figure 1).




Figure 1. Scatter plots of telomere length (T/S ratio log_e transformed and Z standardised) by lithium prescription count, total duration of use, and duration of the first prescription period. The lines were estimated using ordinary least squares regression, and the shaded areas correspond to 95% confidence intervals. Lithium use (yes/no) at the time of the baseline assessment when telomere length was measured is shown in different colours. Individuals without baseline data on current lithium use are not shown. Tx = treatment; Rx = prescription.

Duration of lithium use, frailty and metabolomic age

208

209

210

211

212

213

214

215

216

217

218

219

222

223 224

225

226

There was no evidence that the duration of lithium use was associated with the frailty index (N = 585, β = -0.012, 95% CI -0.030 to 0.006, p = 0.21) or the metabolomic ageing clock (N = $120, \beta = 0.030, 95\%$ CI -0.133 to 0.194, p = 0.72) (Figure 2). This finding was consistent across all measures of the duration of lithium use and adjustment for additional covariates (Table 1).




Figure 2. Scatter plots of telomere length (T/S ratio loge transformed and Z standardised), the frailty index, and the metabolomic ageing clock delta by total duration of lithium use. The lines were estimated using ordinary least squares regression, and the shaded areas correspond to 95% confidence intervals. Tx = treatment.

Table 2. Associations between the duration of lithium use and biological ageing markers

	Model 1 (adj. for age and sex)					Model 2 (full adjustment)					
	n Beta	95% CI		p	n	Beta	95% CI	[p		
Telomere length											
Rx count	569-0.022	-0.081	0.037	0.47	56	7-0.017	-0.076	0.043	0.58		
Total duration	569-0.005	-0.023	0.013	0.57	56	7-0.004	-0.022	0.015	0.71		
Duration first Rx	569-0.018	-0.051	0.015	0.29	56	7-0.014	-0.048	0.019	0.40		
Frailty index											
Rx count	585 -0.045	-0.104	0.014	0.13	580	0-0.043	-0.091	0.004	0.08		
Total duration	585-0.012	-0.030	0.006	0.21	580	0-0.013	-0.028	0.001	0.07		
Duration first Rx	585-0.027	-0.060	0.007	0.12	580	0-0.021	-0.048	0.007	0.14		
Metabolomic age											
Rx count	120-0.036	-0.590	0.518	0.90	120	0-0.022	-0.583	0.540	0.94		
Total duration	1200.030	-0.133	0.194	0.72	120	0-0.009	-0.180	0.161	0.91		
Duration first Rx	1200.248	-0.079	0.576	0.14	120	00.208	-0.128	0.543	0.22		
Pulse rate											
Rx count	586-0.061	-0.119	-0.002	0.04	583	3-0.058	-0.116	0.0001	0.05		
Total duration	586-0.026	-0.044	-0.008	0.005	583	3-0.024	-0.042	-0.006	0.01		
Duration first Rx	586-0.021	-0.055	0.012	0.21	583	3-0.022	-0.056	0.011	0.18		

Note: The measurement units have been rescaled. The number of prescriptions were analysed in units of 50 prescriptions; the total duration of use and the duration of the first prescription period were expressed in years. Model 1 was adjusted for age and sex; Model 2 was adjusted for age, sex, body mass index, morbidity count, household income, highest qualification and cohabitation status. Rx = prescription; CI = confidence interval.

Duration of lithium use and pulse rate

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

To ensure that the lack of statistically significant associations was not due to how we defined the duration of lithium use, we further tested associations between the duration of lithium use and pulse rate (Figure S2). The number of lithium prescriptions (N = 586, $\beta = -0.061$, 95% CI -0.119 to -0.002, p = 0.04) and the total duration of lithium use (N = 586, $\beta = -0.026$, 95% CI -0.044 to -0.008, p = 0.005) were both associated with a lower pulse rate (Table 1).

Duration of lithium use and all-cause mortality

The median duration of follow-up of censored individuals was 13.71 years (IQR = 1.35 years), with more than 7686 person-years of follow-up. During this period, 94 deaths were observed. There was no evidence that the duration of lithium use predicted all-cause mortality. Comparing individuals in the second to fifth quintile of the distribution of the duration of lithium use to individuals in the first quintile resulted in no statistically significant differences in all-cause mortality (lowest p = 0.08) (Figure 3).




Figure 3. Hazard ratios (HR) and 95% confidence intervals from Cox proportional hazards models for all-cause mortality. Age (in years) was used as the underlying time axis. The model was adjusted for age and sex. Reference group: individuals in the lowest quintile of the distribution of the duration of lithium use (prescription count, total duration and duration of the first prescription period). Tx = treatment; Rx = prescription.

Table 3. Associations between the duration of lithium use and all-cause mortality

		Model 1 (adj. for age and sex)						Model 2 (full adjustment)					
		N _{total}	N_{died}	HR	95% CI		p	N _{total} N _{died}		HR	95% CI		p
Rx c	Rx count												
1st	≤ 7	119	19	Refe	rence			118	19	Refer	ence		
2nd	8-23	118	16	0.68	0.34	1.36	0.28	116	15	0.53	0.26	1.09	0.08
3rd	24-60	118	19	0.88	0.46	1.69	0.70	117	19	0.74	0.37	1.48	0.40
4th	61-114	118	18	0.71	0.37	1.38	0.32	118	18	0.68	0.34	1.35	0.27
5th	≥ 115	118	25	1.05	0.57	1.93	0.88	116	25	0.91	0.48	1.74	0.79
Total duration													
1st	≤ 22	119	19	Refe	ence			118	19	Refer	ence		
2nd	23-83	118	14	0.77	0.38	1.54	0.45	117	13	0.61	0.29	1.26	0.18
3rd	84-187	118	19	0.83	0.43	1.62	0.59	115	19	0.74	0.37	1.49	0.40
4th	188-426	118	21	1.15	0.61	2.17	0.66	118	21	0.95	0.50	1.83	0.88
5th	\geq 427	118	24	1.01	0.55	1.86	0.98	117	24	0.91	0.48	1.73	0.78
Dura	ation first	Rx											
1st	≤ 4	119	21	Reference				117	20	Reference			
2nd	5-16	118	17	1.04	0.54	2.00	0.90	118	17	0.96	0.49	1.92	0.92
3rd	17-49	118	13	0.74	0.36	1.53	0.42	117	13	0.71	0.34	1.50	0.37
4th	50-130	118	19	0.95	0.51	1.79	0.88	117	19	1.05	0.54	2.03	0.90
5th	≥ 131	118	27	1.48	0.82	2.66	0.19	116	27	1.46	0.80	2.68	0.22

Note: Hazard ratios and 95% confidence intervals from Cox proportional hazards models for all-cause mortality. Age (in years) was used as the underlying time axis. Model 1 was adjusted for age and sex; Model 2 was adjusted for age, sex, body mass index, morbidity count, household income, highest qualification and cohabitation status. Rx = prescription; HR = hazard ratio; CI = confidence interval.

243

244

245

246

247

248 249

250

Modelling the mortality hazard as a spline function of the duration of lithium use, instead of by quintiles of the distribution, provided little evidence of a statistically significant association between the duration of lithium use and all-cause mortality (Figure 4 and Figure S3). There was, however, some evidence that a prescription count greater than about 300 was associated with a higher mortality risk.




Figure 4. Log hazard ratios and 95% confidence intervals from Cox proportional hazards models for all-cause mortality. Age (in years) was used as the underlying time axis. The model was adjusted for age and sex. Vertical lines indicate the median of the distribution. Tx = treatment; Rx = prescription.

Sensitivity analyses

252

253

254

255

256

257

259

260

261 262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

Excluding participants with a total duration of lithium use of less than 1 year or less than 4.5 years provided little evidence that the duration of lithium use was associated with biological ageing (Table S1 and Table S2). There was some evidence that a longer duration of the first lithium prescription period was associated with a higher MileAge delta, although this finding did not survive multiple testing correction in the fully adjusted model. The duration of lithium use was also not associated with pulse rate in these analyses.

The relationship between telomere length and the duration of lithium use stratified by current antidepressant use at the time of the baseline assessment is shown in Figure S4. Additional adjustment for current antidepressant use had no discernible impact on the analyses of the relationship between the duration of lithium use and biological ageing (Table S3). However, the association between a higher prescription count and a longer total duration of lithium use and pulse rate was stronger in these analyses.

DISCUSSION

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

We examined the relationship between the duration of lithium use and multiple markers of biological ageing, including telomere length, frailty, metabolomic age, and all-cause mortality. Both cross-sectional and prospective analyses provided little evidence of an association between the duration of lithium use and biological ageing or mortality.

Our findings are inconsistent with most prior studies of the duration of lithium use and telomere length, several of which identified a positive association between lithium and telomere length. Martinsson et al. found that lithium-treated bipolar disorder patients had on average 35% longer telomeres than healthy controls.¹⁷ In the same study, the duration of lithium treatment was positively correlated with telomere length, particularly in patients who had been treated for more than 2.5 years. Pisanu et al.34 and Coutts et al.19 corroborated these observations, identifying statistically significant associations between chronic lithium treatment and telomere length in patients with bipolar disorder. Squassina et al. also reported a positive correlation between the duration of lithium use and telomere length in 150 bipolar disorder patients who had been treated for more than two years.³⁵ A mechanistic *in vitro* study provided further evidence supporting lithium's putative effect on telomeres by demonstrating that lithium administration to lymphoblastoid cell lines from bipolar disorder patients increased telomere length.¹⁸ Nevertheless, there is some precedent for our findings. Ferensztajn-Rochowiak et al. reported that in a sample of 41 patients with bipolar disorder, the duration of lithium treatment did not correlate with telomere length in peripheral blood leukocytes.³⁶ Another in vitro study found that administration of lithium to lymphoblastoid cell lines from bipolar disorder patients had no effect on telomere length,³⁷ though it is worth noting that these patients had previously been treated with lithium.

There are several potential explanations for the observed differences between our findings and those of most prior studies. For example, most clinical studies determined the duration of lithium treatment retrospectively during the study visit, while we derived the duration of lithium use in our study from prescription records. Furthermore, there is some evidence that clinical factors such as bipolar disorder diagnosis, number of episodes, chronicity and severity of illness impact telomere length. The participants in our study likely represent a healthier subset of the population than the patients included in prior clinical studies. Moreover, genetic factors can moderate the effect of lithium on telomere length.¹⁹ Although, we adjusted for several confounders in our analyses, we also found little evidence of any statistical associations

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

in the model adjusted only for chronological age and sex. The sample size of our study (n =569) is one of the largest in the field, and we used three definitions of the duration of lithium use to increase the robustness of our findings. In addition, we conducted a sensitivity analysis of pulse rate, which we expected to differ with longer duration of lithium use.³⁸ The observed correlation between the duration of lithium use and a lower pulse rate supports the validity of our measures of the duration of lithium use.

There has been little prior research on the relationship between lithium use and the other biological ageing markers explored in this study. Okazaki et al. found that bipolar disorder patients who were taking mood stabilisers had a younger epigenetic age, according to Horvath's epigenetic ageing clock, than patients who were not taking mood stabilisers.³⁹ However, an *in* vitro study of lymphoblastoid cell lines did not find that administration of lithium impacted the Horvath clock.¹⁸ We found no evidence of an association between the duration of lithium use and metabolomic age in our study. However, it is worth noting that epigenetic and metabolomic age are not strongly correlated. 40 We also explored the relationship between the duration of lithium use and frailty, which is a measure of age-related health deficit accumulation. While some evidence suggests that frailty and telomere length are not strongly linked, 41 frailty is a key marker of biological ageing and physical ill-health. 42,43 Our study provided no evidence of a statistically significant association between the duration of lithium use and frailty. Taken together, these findings suggest that the lack of association between the duration of lithium use and biological ageing – at least in our sample – was not specific to telomere length.

The duration of lithium use was not linked to all-cause mortality in our study. Multiple observational studies have previously shown that lithium use is associated with a lower mortality risk. For example, a cohort study of 826 patients in Finland found that lithium treatment, compared to no lithium use, was associated with a lower all-cause mortality risk.⁴⁴ Another cohort study in Taiwan found that lithium was associated with the lowest all-cause mortality risk in bipolar disorder patients, relative to other mood stabiliser treatments.⁴⁵ A recent study in the UK Biobank also found that lithium treatment was associated with a lower all-cause mortality risk than treatment with antipsychotics. 46 However, it is important to note that we examined the duration of lithium use, not whether patients were treated versus not treated with lithium, which prior studies examined. As such, our findings suggest that there may not be a link between longer duration of lithium use and all-cause mortality in a community-based, real-world sample. These findings do not imply that lithium use (yes/no) is

not linked to all-cause mortality, and they do not invalidate findings from clinical trials where lithium adherence is more controlled and all-cause mortality.

Limitations

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

We acknowledge certain limitations to our study. The UK Biobank primarily recruited individuals between the ages of 40 to 69 years, limiting the conclusions drawn from our findings to middle-aged and older adults. There is evidence of a healthy volunteer participation bias in the UK Biobank, 47,48 which could mean that the participants in our study were healthier than the patients included in prior clinical studies. The observational nature of our study precludes any causal inferences, and residual confounding factors may exist despite our efforts to account for relevant covariates. The duration of lithium use was derived from primary care prescription records. Prescriptions may not perfectly reflect medication use and there is some evidence that, despite the need for regular blood tests, adherence to lithium is poor in clinical practice;⁴⁹ furthermore, prescription dates are a proxy of date of use. Nonetheless, we derived and tested three different definitions of the duration of lithium use to be as robust as possible within these constraints. Telomere length was measured using leukocyte DNA, and findings might differ from telomere length measured in other tissues. However, prior evidence suggests that leukocyte telomere length correlates well with telomere length in other tissues.⁵⁰ Finally, we could only examine average telomere length and were unable to evaluate whether the duration of lithium use was associated with variability in telomere length, which may be more important for telomere dysfunction and biological ageing.²⁶

Conclusion

Our findings, in a larger sample, challenge prior research on the relationship between the duration of lithium use and telomere length. Given that we also did not observe statistically significant associations with other biological ageing markers such as frailty and metabolomic age, nor with all-cause mortality, our findings suggest that the potential anti-ageing effects of lithium do not differ by duration of use. Our findings encourage further scientific inquiry into the complex interplay between lithium medication, biological ageing and lifespan.

ETHICS

376

377

380

381

387

388

401

402

- Ethical approval for the UK Biobank study has been granted by the National Information
- 378 Governance Board for Health and Social Care and the NHS North West Multicentre Research
- 379 Ethics Committee (11/NW/0382). No project-specific ethical approval is needed.

AUTHORSHIP CONTRIBUTIONS

- 382 JM conceived the idea of the study, acquired the data, carried out the statistical analysis,
- interpreted the findings and co-wrote the manuscript. WLEW identified the lithium medication 383
- 384 codes, pre-processed the data to define duration of lithium use, interpreted the findings and co-
- wrote the manuscript. TRP, AHY, GSD and CML interpreted the findings and reviewed the 385
- 386 manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

- 389 This study was funded by the National Institute for Health and Care Research (NIHR)
- 390 Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
- 391 and King's College London. The views expressed are those of the authors and not necessarily
- 392 those of the NHS, the NIHR or the Department of Health and Social Care. WLEW is supported
- 393 by the National University of Singapore President's Graduate Fellowship. TRP is supported by
- the MRC (UKRI) as part of a New Investigator Research Grant [MR/W028018/1]. GSD is 394
- supported by the Ministry of Education, Singapore, under its Academic Research Fund Tier 3 395
- 396 Award (MOE2017-T3-1-002). This research has been conducted using data from UK Biobank,
- 397 a major biomedical database. Data access permission has been granted under UK Biobank
- application 45514. All analyses were supported by: King's College London. (2023). King's 398
- 399 Computational Research, Engineering and Technology Environment (CREATE). Retrieved
- 400 May 24, 2023, from https://doi.org/10.18742/rnvf-m076

FINANCIAL DISCLOSURES

- 403 AHY declares the following: paid lectures and advisory boards for companies with drugs used
- 404 in affective and related disorders (Flow Neuroscience, Novartis, Roche, Janssen, Takeda,
- 405 Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck,
- 406 Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma,
- 407 Sage and Neurocentrx); principal investigator in the Restore-Life VNS registry study funded
- 408 by LivaNova; principal investigator on "ESKETINTRD3004: An Open-label, Long-term,
- 409 Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression";

410 principal investigator on "The Effects of Psilocybin on Cognitive Function in Healthy 411 Participants"; principal investigator on "The Safety and Efficacy of Psilocybin in Participants 412 with Treatment-Resistant Depression (P-TRD)"; principal investigator on "A Double-Blind, 413 Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to 414 Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to 415 Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia 416 Symptoms Who Have Responded Inadequately to Antidepressant Therapy" (Janssen); 417 principal investigator on "An Open-label, Long-term, Safety and Efficacy Study of Aticaprant 418 as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder 419 (MDD)" (Janssen); principal investigator on "A Randomized, Double-blind, Multicentre, 420 Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 421 Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder 422 (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current 423 Antidepressant Therapy"; principal investigator on "A Study of Disease Characteristics and 424 Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) 425 With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an 426 SSRI or SNR" (Janssen); UK chief investigator for Compass COMP006 & COMP007 studies; 427 UK chief investigator for Novartis MDD study MIJ821A12201; grant funding (past and 428 present) from NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research 429 Institute (USA), MRC (UK), Wellcome Trust (UK), Royal College of Physicians (Edin), BMA 430 (UK), UBC-VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund 431 (Canada), MSFHR (Canada), NIHR (UK), Janssen (UK) and EU Horizon 2020. No 432 shareholdings in pharmaceutical companies. CML sits on the scientific advisory board for 433 Myriad Neuroscience, has received speaker fees from SYNLAB, and consultancy fees from 434 UCB. JM, WLEW, TRP and GSD declare no financial conflict of interest.

DATA SHARING STATEMENT

435

436

437

438

439

UK Biobank data used are available to all bona fide researchers for health-related research that is in the public interest, subject to an application process and approval criteria. Study materials are publicly available online at http://www.ukbiobank.ac.uk.

REFERENCES

- 441 1. National Institute for Health Care Excellence. Bipolar disorder: assessment and
- 442 management. 2020.

440

- 443 Cleare A, Pariante C, Young A, et al. Evidence-based guidelines for treating depressive 2.
- 444 disorders with antidepressants: A revision of the 2008 British Association for
- Psychopharmacology guidelines. Journal of Psychopharmacology 2015; 29(5): 459-525. 445
- 446 3. Gadelrab R, Hampsey E, Strawbridge R, Taylor RH, Ulrichsen A, Young AH.
- 447 Comparing measurements of lithium treatment efficacy in people with bipolar disorder:
- 448 systematic review and meta-analysis. BJPsych Open 2023; 9(3): e98.
- 449 Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential Mechanisms of Action
- 450 of Lithium in Bipolar Disorder. CNS Drugs 2013; 27(2): 135-53.
- Salarda EM, Zhao NO, Lima CNNC, Fries GR. Mini-review: The anti-aging effects of 451
- 452 lithium in bipolar disorder. Neuroscience Letters 2021; 759: 136051.
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: 453 6.
- 454 An expanding universe. Cell 2023; 186(2): 243-78.
- 455 7. Maurer IC, Schippel P, Volz H-P. Lithium-induced enhancement of mitochondrial
- 456 oxidative phosphorylation in human brain tissue. Bipolar Disorders 2009; 11(5): 515-22.
- 457 8. de Sousa RT, Streck EL, Zanetti MV, et al. Lithium increases leukocyte mitochondrial
- 458 complex I activity in bipolar disorder during depressive episodes. *Psychopharmacology* 2015;
- **232**(1): 245-50. 459
- Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in 460 9.
- 461 unmedicated and treated bipolar subjects during initial manic episode: A possible role for
- 462 lithium antioxidant effects. Neuroscience Letters 2007; 421(1): 33-6.
- 463 Khairova R, Pawar R, Salvadore G, et al. Effects of lithium on oxidative stress
- 464 parameters in healthy subjects. Mol Med Rep 2012; 5(3): 680-2.
- 465 McColl G, Killilea DW, Hubbard AE, Vantipalli MC, Melov S, Lithgow GJ.
- 466 Pharmacogenetic Analysis of Lithium-induced Delayed Aging in Caenorhabditis elegans.
- Journal of Biological Chemistry 2008; 283(1): 350-7. 467
- 468 Castillo-Quan Jorge I, Li L, Kinghorn Kerri J, et al. Lithium Promotes Longevity 12.
- 469 through GSK3/NRF2-Dependent Hormesis. Cell Reports 2016; 15(3): 638-50.
- 470 13. Rossiello F, Jurk D, Passos JF, d'Adda di Fagagna F. Telomere dysfunction in ageing
- 471 and age-related diseases. Nature Cell Biology 2022; 24(2): 135-47.

- 472 14. Colpo GD, Leffa DD, Köhler CA, Kapczinski F, Quevedo J, Carvalho AF. Is bipolar
- 473 disorder associated with accelerating aging? A meta-analysis of telomere length studies.
- 474 Journal of Affective Disorders 2015; 186: 241-8.
- 475 Darrow SM, Verhoeven JE, Révész D, et al. The Association Between Psychiatric 15.
- 476 Disorders and Telomere Length: A Meta-Analysis Involving 14,827 Persons. *Psychosomatic*
- 477 Medicine 2016; **78**(7): 776-87.
- 478 16. Huang Y-C, Wang L-J, Tseng P-T, Hung C-F, Lin P-Y. Leukocyte telomere length in
- 479 patients with bipolar disorder: An updated meta-analysis and subgroup analysis by mood status.
- 480 Psychiatry Research 2018; 270: 41-9.
- 481 Martinsson L, Wei Y, Xu D, et al. Long-term lithium treatment in bipolar disorder is
- 482 associated with longer leukocyte telomeres. Translational Psychiatry 2013; 3(5): e261-e.
- Fries GR, Zamzow MJ, Colpo GD, et al. The anti-aging effects of lithium in 483
- 484 lymphoblastoid cell lines from patients with bipolar disorder and controls. Journal of
- 485 Psychiatric Research 2020; 128: 38-42.
- 486 19. Coutts F, Palmos AB, Duarte RRR, et al. The polygenic nature of telomere length and
- 487 the anti-ageing properties of lithium. Neuropsychopharmacology 2019; 44(4): 757-65.
- 488 20. Mutz J, Lewis CM. Telomere Length Associations With Clinical Diagnosis, Age, and
- 489 Polygenic Risk Scores for Anxiety Disorder, Depression, and Bipolar Disorder. Biological
- 490 Psychiatry Global Open Science 2023; **3**(4): 1012-20.
- 491 21. Bountziouka V, Musicha C, Allara E, et al. Modifiable traits, healthy behaviours, and
- 492 leukocyte telomere length: a population-based study in UK Biobank. The Lancet Healthy
- 493 Longevity 2022; **3**(5): e321-e31.
- 494 Luo S, Wong ICK, Chui CSL, et al. Effects of putative metformin targets on phenotypic 22.
- 495 age and leukocyte telomere length: a mendelian randomisation study using data from the UK
- 496 Biobank. The Lancet Healthy Longevity 2023; 4(7): e337-e44.
- 497 23. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
- 498 phenotyping and genomic data. Nature 2018; 562(7726): 203-9.
- 499 24. Wong WL, Fabbri C, Laplace B, et al. The Effects of CYP2C19 Genotype on Proxies
- 500 of SSRI Antidepressant Response in the UK Biobank. Pharmaceuticals, 2023. (accessed.
- 501 Codd V, Denniff M, Swinfield C, et al. Measurement and initial characterization of 25.
- 502 leukocyte telomere length in 474,074 participants in UK Biobank. *Nature Aging* 2022; **2**(2):
- 170-9. 503

- 504 26. Lai T-P, Wright WE, Shay JW. Comparison of telomere length measurement methods.
- 505 Philosophical Transactions of the Royal Society B: Biological Sciences 2018; 373(1741):
- 506 20160451.
- 507 Williams DM, Jylhävä J, Pedersen NL, Hägg S. A Frailty Index for UK Biobank 27.
- 508 Participants. The Journals of Gerontology: Series A 2018; 74(4): 582-7.
- 509 28. Mutz J, Choudhury U, Zhao J, Dregan A. Frailty in individuals with depression, bipolar
- 510 disorder and anxiety disorders: longitudinal analyses of all-cause mortality. BMC Medicine
- 511 2022; **20**(1): 274.
- 512 29. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
- Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: 513
- 514 A Primer on -Omic Technologies. American Journal of Epidemiology 2017; **186**(9): 1084-96.
- Ouinlan JR. Learning with continuous classes. 5th Australian joint conference on 515 30.
- artificial intelligence; 1992: World Scientific; 1992. p. 343-8. 516
- 517 31. Kuhn M, Johnson K. Regression Trees and Rule-Based Models. In: Kuhn M, Johnson
- 518 K, eds. Applied Predictive Modeling. New York, NY: Springer New York; 2013: 173-220.
- 519 32. Mutz J, Lewis CM. Lifetime depression and age-related changes in body composition,
- 520 cardiovascular function, grip strength and lung function: sex-specific analyses in the UK
- 521 Biobank. Aging 2021; 13(13): 17038-79.
- 522 Mutz J, Young AH, Lewis CM. Age-related changes in physiology in individuals with 33.
- bipolar disorder. Journal of Affective Disorders 2022; 296: 157-68. 523
- 524 Pisanu C, Congiu D, Manchia M, et al. Differences in telomere length between patients 34.
- 525 with bipolar disorder and controls are influenced by lithium treatment. Pharmacogenomics
- 526 2020; **21**(8): 533-40.
- 527 35. Squassina A, Pisanu C, Congiu D, et al. Leukocyte telomere length positively correlates
- 528 lithium in bipolar with of treatment disorder patients. European
- 529 Neuropsychopharmacology 2016; **26**(7): 1241-7.
- 530 Ferensztajn-Rochowiak E, Hołysz H, Kurczewska E, et al. Decreased leucocyte
- 531 telomere length in male patients with chronic bipolar disorder: lack of effect of long-term
- 532 lithium treatment. Acta Neuropsychiatrica 2021; 33(6): 299-306.
- 533 Squassina A, Meloni A, Congiu D, et al. Analysis on in vitro effect of lithium on 37.
- 534 telomere length in lymphoblastoid cell lines from bipolar disorder patients with different
- 535 clinical response to long-term lithium treatment. Human Genomics 2022; 16(1): 45.
- 536 Mehta N, Vannozzi R. Lithium-induced electrocardiographic changes: A complete 38.
- 537 review. Clinical Cardiology 2017; 40(12): 1363-7.

- 538 39. Okazaki S, Numata S, Otsuka I, et al. Decelerated epigenetic aging associated with
- 539 mood stabilizers in the blood of patients with bipolar disorder. Translational Psychiatry 2020;
- 540 **10**(1): 129.
- 541 40. Robinson O, Chadeau Hyam M, Karaman I, et al. Determinants of accelerated
- metabolomic and epigenetic aging in a UK cohort. Aging Cell 2020; 19(6): e13149. 542
- Araújo Carvalho AC, Tavares Mendes ML, da Silva Reis MC, Santos VS, Tanajura 543 41.
- 544 DM, Martins-Filho PRS. Telomere length and frailty in older adults—A systematic review and
- 545 meta-analysis. Ageing Research Reviews 2019; 54: 100914.
- 546 42. Ji L, Jazwinski SM, Kim S. Frailty and Biological Age. Ann Geriatr Med Res 2021;
- 547 **25**(3): 141-9.
- 43. 548 Mitnitski A, Collerton J, Martin-Ruiz C, et al. Age-related frailty and its association
- 549 with biological markers of ageing. BMC Medicine 2015; 13(1): 161.
- 550 44. Toffol E, Hätönen T, Tanskanen A, et al. Lithium is associated with decrease in all-
- cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based 551
- 552 prospective cohort study. Journal of Affective Disorders 2015; 183: 159-65.
- 553 45. Chen P-H, Tsai S-Y, Chen P-Y, et al. Mood stabilizers and risk of all-cause, natural,
- 554 and suicide mortality in bipolar disorder: A nationwide cohort study. Acta Psychiatrica
- 555 Scandinavica 2023; 147(3): 234-47.
- 556 46. Araldi E, Jutzeler CR, Ristow M. Lithium treatment extends human lifespan: findings
- from the UK Biobank. Aging (Albany NY) 2023; 15(2): 421-40. 557
- Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-558 47.
- 559 Related Characteristics of UK Biobank Participants With Those of the General Population.
- 560 American Journal of Epidemiology 2017; **186**(9): 1026-34.
- 561 Schoeler T, Speed D, Porcu E, Pirastu N, Pingault J-B, Kutalik Z. Participation bias in
- 562 the UK Biobank distorts genetic associations and downstream analyses. Nature Human
- 563 Behaviour 2023; 7(7): 1216-27.
- 564 49. Johnson R, McFarland B. Lithium use and discontinuation in a health maintenance
- organization. American Journal of Psychiatry 1996; 153(8): 993-1000. 565
- 566 Demanelis K, Jasmine F, Chen LS, et al. Determinants of telomere length across human 50.
- 567 tissues. Science 2020; 369(6509): eaaz6876.